RWC Asset Management LLP Buys Shares of 6,147 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

RWC Asset Management LLP purchased a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,147 shares of the medical device company’s stock, valued at approximately $221,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Baillie Gifford & Co. grew its position in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock worth $26,875,000 after acquiring an additional 523,843 shares during the period. Bellevue Group AG increased its holdings in Tandem Diabetes Care by 19.9% in the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after purchasing an additional 307,624 shares during the last quarter. Stephens Investment Management Group LLC lifted its position in shares of Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock worth $56,040,000 after purchasing an additional 281,327 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Tandem Diabetes Care by 397.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock worth $11,121,000 after purchasing an additional 240,966 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at $10,208,000.

Tandem Diabetes Care Trading Down 3.5 %

Shares of TNDM stock opened at $31.00 on Monday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 1 year low of $24.42 and a 1 year high of $53.69. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -16.06 and a beta of 1.32. The company’s fifty day simple moving average is $35.48 and its two-hundred day simple moving average is $36.70.

Analysts Set New Price Targets

TNDM has been the subject of a number of research reports. Citigroup reduced their price objective on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price for the company in a research report on Monday, December 2nd. Canaccord Genuity Group dropped their price objective on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Robert W. Baird reduced their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.81.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.